New hope for UC patients: early biologic treatment may beat standard therapy

This study compares two treatment approaches for people newly diagnosed with moderate-to-severe ulcerative colitis (UC). One group gets early treatment with mirikizumab, a biologic drug, while the other starts with standard azathioprine pills and can switch to mirikizumab later if needed. The goal is to see if starting with mirikizumab leads to better disease control and fewer side effects over 52 weeks. About 300 adults will take part.